An evaluation of statistical approaches to postmarketing surveillance
暂无分享,去创建一个
[1] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[2] Bradley P. Carlin,et al. Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials , 2011, Journal of biopharmaceutical statistics.
[3] B. Stricker,et al. Serum sickness-like reactions to cefaclor. , 1992, Journal of clinical epidemiology.
[4] G. D. Dal Pan,et al. Evaluation of FDA safety‐related drug label changes in 2010 , 2013, Pharmacoepidemiology and drug safety.
[5] Ram C Tiwari,et al. Likelihood Ratio Test-Based Method for Signal Detection in Drug Classes Using FDA's AERS Database , 2013, Journal of biopharmaceutical statistics.
[6] Qi Jiang,et al. Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials , 2018, Therapeutic innovation & regulatory science.
[7] C Chuang-Stein,et al. Organization and analysis of safety data using a multivariate approach. , 1992, Statistics in medicine.
[8] Manfred Hauben,et al. An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database , 2010, Drug safety.
[9] R. Tiwari,et al. A Review of Statistical Methods for Safety Surveillance , 2014, Therapeutic innovation & regulatory science.
[10] Richard C. Zink,et al. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance , 2018, Therapeutic innovation & regulatory science.
[11] S. Evans,et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.
[12] John Ihrie,et al. openEBGM: An R Implementation of the Gamma-Poisson Shrinker Data Mining Model , 2017, R J..
[13] Sushil Ghimire,et al. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database , 2017, Pharmacoepidemiology and drug safety.
[14] F Thiessard,et al. False Discovery Rate Estimation for Frequentist Pharmacovigilance Signal Detection Methods , 2010, Biometrics.
[15] Johan Hopstadius,et al. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery , 2011, Statistical methods in medical research.
[16] William DuMouchel,et al. Empirical bayes screening for multi-item associations , 2001, KDD '01.
[17] Chieko Ishiguro,et al. Post‐market drug safety evidence sources: an analysis of FDA drug safety communications , 2012, Pharmacoepidemiology and drug safety.
[18] F Thiessard,et al. Pharmacovigilance Data Mining With Methods Based on False Discovery Rates: A Comparative Simulation Study , 2010, Clinical pharmacology and therapeutics.
[19] A Lawrence Gould,et al. Practical pharmacovigilance analysis strategies. , 2003, Pharmacoepidemiology and drug safety.
[20] G. Niklas Norén,et al. Good Signal Detection Practices: Evidence from IMI PROTECT , 2016, Drug Safety.
[21] Kristina Juhlin,et al. Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases , 2016, Drug Safety.
[22] Qi Jiang,et al. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights , 2018, Therapeutic innovation & regulatory science.
[23] G. Hommel. A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .
[24] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[25] Kristina Juhlin,et al. Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases , 2015, Drug Safety.
[26] S. Dudoit,et al. Multiple Hypothesis Testing in Microarray Experiments , 2003 .
[27] Ram Tiwari,et al. Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection , 2017, Statistical methods in medical research.
[28] S. Holm. A Simple Sequentially Rejective Multiple Test Procedure , 1979 .
[29] G. D. Dal Pan,et al. Estimating the extent of reporting to FDA: a case study of statin‐associated rhabdomyolysis , 2008, Pharmacoepidemiology and drug safety.
[30] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[31] D. Madigan,et al. The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.
[32] Ismaïl Ahmed,et al. Implementation of an automated signal detection method in the French pharmacovigilance database: a feasibility study , 2011, European Journal of Clinical Pharmacology.
[33] Na Hu,et al. Signal detection in FDA AERS database using Dirichlet process , 2015, Statistics in medicine.
[34] S. Anderson,et al. The FDA's sentinel initiative—A comprehensive approach to medical product surveillance , 2016, Clinical pharmacology and therapeutics.
[35] Christy Chuang-Stein,et al. The Practice of Pre-Marketing Safety Assessment in Drug Development , 2013, Journal of biopharmaceutical statistics.
[36] Ismaïl Ahmed,et al. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting , 2009, Statistics in medicine.
[37] M. Lindquist,et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.
[38] Y. Benjamini,et al. THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .
[39] Manfred Hauben,et al. A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality , 2017, Therapeutic advances in drug safety.
[40] Sania Amr,et al. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014 , 2018, Clinical pharmacology and therapeutics.
[41] A. Bate,et al. A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.
[42] Marianthi Markatou,et al. A pattern discovery framework for adverse event evaluation and inference in spontaneous reporting systems , 2014, Stat. Anal. Data Min..
[43] R. Tiwari,et al. A Likelihood Ratio Test Based Method for Signal Detection With Application to FDA’s Drug Safety Data , 2011 .
[44] Min Yi,et al. Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA’s adverse event reporting system database , 2018, Statistical methods in medical research.
[45] Richard Platt,et al. The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.
[46] Ram Tiwari,et al. Likelihood ratio based tests for longitudinal drug safety data. , 2014, Statistics in medicine.
[47] Jesse A Berlin,et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team , 2009, Clinical trials.